Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.


    The EU Clinical Trials Register currently displays   42867   clinical trials with a EudraCT protocol, of which   7062   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).


    Phase 1 trials conducted solely in adults and that are not part of an agreed PIP are not public in the EU CTR (refer to European Guidance 2008/C 168/02   Art. 3 par. 2 and   Commission Guideline 2012/C 302/03,   Art. 5) .

    Clinical Trials marked as "Trial now transitioned" were transitioned to the Clinical Trial Regulation 536/2014 and can be further followed in the Clinical Trial Information System  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2015-004405-16
    Sponsor's Protocol Code Number:SNT-IV-005
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Ongoing
    Date on which this record was first entered in the EudraCT database:2016-03-18
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2015-004405-16
    A.3Full title of the trial
    External Natural History Controlled, open-Label Intervention Study to Assess the Efficacy and Safety of Long-Term Treatment with Raxone® in Leber?s Hereditary Optic Neuropathy (LHON)
    Estudio de intervención abierto controlado por grupo de evolución natural externo para evaluar la eficacia y la seguridad del tratamiento prolongado con Raxone® en la neuropatía óptica hereditaria de Leber (NOHL)
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Clinical study to assess the effectiveness and safety of Raxone during long time treatment in patients with LHON
    Estudio clinico para evaluar la efectividad y la seguridad con Raxone durante el tratamiento prolongado en pacientes con NOHL.
    A.3.2Name or abbreviated title of the trial where available
    (LEROS) Open- Label Study to assess the Efficacy and Safety of Raxone in LHON Patients
    (LEROS) Estudio abierto para evaluar la eficacia y seguridad de Raxone en NOHL
    A.4.1Sponsor's protocol code numberSNT-IV-005
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorSanthera Pharmaceuticals (Switzerland) Limited
    B.1.3.4CountrySwitzerland
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportSanthera Pharmaceuticals
    B.4.2CountrySwitzerland
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationSanthera Pharmaceuticals (Switzerland) Ltd
    B.5.2Functional name of contact pointMedical Affairs Director
    B.5.3 Address:
    B.5.3.1Street AddressVia I. Rosellini 12
    B.5.3.2Town/ cityMilan
    B.5.3.3Post code20124
    B.5.3.4CountryItaly
    B.5.4Telephone number34686 935 930
    B.5.6E-mailXavier.Lloria@santhera.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Raxone
    D.2.1.1.2Name of the Marketing Authorisation holderSanthera Pharmaceuticals (Deutschland) GmbH
    D.2.1.2Country which granted the Marketing AuthorisationEuropean Union
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community Yes
    D.2.5.1Orphan drug designation numberEU/3/07/434
    D.3 Description of the IMP
    D.3.4Pharmaceutical form Film-coated tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNidebenone
    D.3.9.1CAS number 58186-27-9
    D.3.9.3Other descriptive nameIDEBENONE
    D.3.9.4EV Substance CodeSUB08114MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number150
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Leber?s Hereditary Optic Neuropathy / LHON is a maternally inherited loss of vision due to atrophy of the optic nerve. It typically presents in young adults, mostly men, as painless acute or subacute visual failure of both eyes in quick succession. The estimated prevalence is approximately 2.2 per 100,000 (Mascialino et al., 2012) and LHON is thus an Orphan Disease according to EU and US criteria.
    La NOHL consiste en una pérdida de visión heredada por vía materna que se debe a una atrofia del nervio óptico. Normalmente se presenta en adultos jóvenes, principalmente varones, como pérdida visual aguda o subaguda indolora de ambos ojos en rápida sucesión. La prevalencia estimada es de aproximadamente el 2,2 por 100 000 (Mascialino et al., 2012), por lo que la NOHL es una enfermedad rara según los criterios de la UE y los EE. UU.
    E.1.1.1Medical condition in easily understood language
    Raxone is a medicine used to treat Leber?s hereditary optic neuropathy (LHON), a rare hereditary disease that can lead to blindness.
    Raxone es un medicamento utilizado para tratar la neuropatía óptica hereditaria de Leber (NOHL), una enfermedad hereditaria rara que puede conducir a la ceguera.
    E.1.1.2Therapeutic area Diseases [C] - Eye Diseases [C11]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 18.1
    E.1.2Level LLT
    E.1.2Classification code 10062951
    E.1.2Term Leber's hereditary optic atrophy neuropathy
    E.1.2System Organ Class 100000004850
    E.1.3Condition being studied is a rare disease Yes
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To assess efficacy of Raxone® in the promotion of recovery or stabilization of visual acuity in patients treated with Raxone® ?1 year after the onset of symptoms, compared to an external natural history control group of idebenone naïve patients
    Evaluar la eficacia de Raxone® en la estimulación de la recuperación o estabilización de la agudeza visual en pacientes tratados con Raxone® ? 1 año después de la aparición de los síntomas, en comparación con un grupo de control de evolución natural externo de pacientes no tratados anteriormente con idebenona.
    E.2.2Secondary objectives of the trial
    ? To assess efficacy of Raxone® in the promotion of recovery or stabilization of vision in LHON patients treated with Raxone® >1 year after the onset of symptoms, compared to an external natural history control group of idebenone naïve patients
    ? To compare the promotion of recovery or stabilization of visual acuity in LHON patients treated with Raxone® ?1 and >1 year after the onset of symptoms
    ? To assess the influence of mutation on the promotion of recovery or stabilization of visual acuity in LHON patients treated with Raxone®
    ? To assess the influence of time since onset of symptoms prior to the initiation of treatment with Raxone® on the promotion of recovery or stabilization of visual acuity in LHON patients
    ? To assess the influence of duration of treatment with Raxone® on changes in visual acuity in LHON patients
    ? To assess safety of long-term treatment of LHON patients with Raxone®
    ? Evaluar la eficacia de Raxone® en la estimulación de la recuperación o estabilización de la visión en pacientes con NOHL tratados con Raxone® > 1 año después de la aparición de los síntomas, en comparación con un grupo de control de evolución natural externo de pacientes que no han recibido tratamiento anteriormente con idebenona. /Comparar la estimulación de la recuperación o estabilización de la agudeza visual en pacientes con NOHL tratados con Raxone® ? 1 y > 1 año después de la aparición de los síntomas. /Evaluar la influencia de la mutación en la estimulación de la recuperación o estabilización de la agudeza visual en pacientes con NOHL tratados con Raxone®. /Evaluar la influencia del tiempo desde la aparición de los síntomas antes del inicio del tratamiento con Raxone® sobre la estimulación de la recuperación o estabilización de la agudeza visual en pacientes con NOHL. /Por favor ver la sección ¨Criterios de valoración secundarios¨de la synopsis para ver los puntos no incluidos
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    The following criteria should be assessed during Baseline Visit before randomization. If any does not apply, the patient must not be included in the study:
    1. Impaired visual acuity in affected eyes due to LHON
    2. No explanation for visual loss besides LHON
    3. Age?12 years
    4. Onset of symptoms ?5 years prior to Baseline
    5. Confirmation of either G11778A, G3460A or T14484C LHON mtDNA (for the ITT population, not required for enrolment)
    6. Written informed consent obtained from the patient
    7. Ability and willingness to comply with study procedures and visits
    8. Women of Childbearing Potential (WCBP) who have a negative urine or serum pregnancy test at Baseline visit and who are willing to use a highly effective contraceptive measure and maintain it until treatment discontinuation
    Se deben evaluar los siguientes criterios durante la visita inicial antes de la aleatorización. Si no se cumple alguno de ellos, no se deberá incluir al paciente en el estudio:
    1. Deterioro de la agudeza visual en los ojos afectados por la NOHL
    2. Pérdida de visión que no se explica por otra causa aparte de la NOHL
    3. Edad +o=12 años
    4. Inicio de los síntomas ? 5 años antes del inicio del estudio
    5. Confirmación de la mutación en el ADNmt de NOHL G11778A, G3460A o T14484C
    (para la población ITT, no es necesario para la inscripción)
    6. Consentimiento informado por escrito obtenido del paciente
    7. Capacidad y disposición a cumplir los procedimientos y las visitas del estudio
    8. Mujeres en edad fértil (MEF) que tengan una prueba de embarazo en orina o en suero negativa en la visita inicial y que estén dispuestas a utilizar un método anticonceptivo altamente eficaz y mantenerlo hasta la interrupción del tratamiento
    E.4Principal exclusion criteria
    The following criteria should be checked during Baseline Visit before randomization. If any applies, the patient must not be included in the study:
    1. Patient has provided natural history data to the Case Record Survey (SNT-CRS-002)
    2. Any previous use of idebenone
    3. Any other cause of visual impairment (e.g. glaucoma, diabetic retinopathy, AIDS related visual impairment, cataract, macular degeneration, etc.) or any active ocular disorder (uveitis, infections, inflammatory retinal disease, thyroid eye disease, etc.)
    4. Known history of clinically significant elevations (greater than 3 times the upper limit of normal) of AST, ALT or creatinine
    5. Patient has a condition or is in a situation which, in an investigator?s opinion may put the patient at significant risk, may confound study results or may interfere significantly with the patient?s participation in the study
    6. Participation in another clinical trial of any investigational drug within 3 months prior to Baseline
    7. Hypersensitivity to the active substance or to any of the following excipients (as listed in section 6.1 of Raxone SmPC): Lactose monohydrate, Microcrystalline cellulose, Croscarmellose sodium, Povidone K25, Magnesium stearate, Colloidal silica, Macrogol 3350, Poly(vinyl alcohol), Talc, Titanium dioxide, Sunset yellow FCF (E110).
    8. Women who are pregnant or have a positive pregnancy test at Baseline visit
    9. Women who are breastfeeding
    Se deben comprobar los siguientes criterios durante la visita inicial antes de la aleatorización. Si alguno se cumple, no se deberá incluir al paciente en el estudio:
    1. El paciente ha proporcionado datos de evolución natural para el estudio de registro de casos (SNT-CRS-002).
    2. Cualquier uso previo de idebenona.
    3. Cualquier otra causa de deficiencia visual (p. ej., glaucoma, retinopatía diabética, deficiencia visual relacionada con el SIDA, cataratas, degeneración macular, etc.) o cualquier trastorno ocular activo (uveítis, infecciones, enfermedad inflamatoria de la retina, enfermedad de Graves, etc.).
    4. Antecedentes conocidos de elevaciones clínicamente significativas (superiores a tres veces el límite superior de la normalidad) de AST, ALT o creatinina.
    5. El paciente tiene una afección o está en una situación que, en opinión del investigador, puede ponerle en riesgo importante, puede confundir los resultados del estudio o puede interferir de forma significativa con la participación del paciente en el estudio.
    6. Participación en otro ensayo clínico de cualquier fármaco en investigación en los tres meses previos al inicio del estudio.
    7. Hipersensibilidad al principio activo o a alguno de los excipientes siguientes (que se enumeran en la sección 6.1 del RCP de Raxone): lactosa monohidrato, celulosa microcristalina, croscarmelosa sódica, povidona K25, estearato de magnesio, sílice coloidal, macrogol 3350, alcohol poli(vinílico), talco, dióxido de titanio, amarillo anaranjado FCF (E110).
    8. Mujeres embarazadas o que tienen una prueba de embarazo positiva en la visita inicial
    9. Mujeres en periodo de lactancia
    E.5 End points
    E.5.1Primary end point(s)
    Proportion of eyes with clinically relevant recovery of VA from Baseline or in which Baseline VA better than 1.0 logMAR was maintained at Month 12 in patients treated with Raxone® ?1 year after the onset of symptoms, compared to matching external natural history control group
    Clinically Relevant Recovery (CRR) is defined as a change from ?off-chart? visual acuity (VA) to at least 1.6 logMAR value or an improvement of at least 0.2 logMAR value within ?on-chart?.
    Proporción de ojos con recuperación clínicamente relevante de la AV con respecto al valor inicial o en los que la AV inicial mejor de 1,0 logMAR se mantenía en el mes 12 en los pacientes tratados con Raxone® ? 1 año después de la aparición de los síntomas, en comparación con el grupo de control de evolución natural externo correspondiente.
    La recuperación clínicamente relevante (RCR) se define como un cambio en la agudeza visual (AV) ?sin optotipo? hasta al menos un valor de 1,6 logMAR o una mejora de al menos un valor de 0,2 logMAR ?con optotipo?.
    E.5.1.1Timepoint(s) of evaluation of this end point
    see E.5.1 text
    Ver el texto E.5.1
    E.5.2Secondary end point(s)
    ? Components of the primary endpoint:
    - Proportion of eyes with CRR of VA from Baseline at Month 12 compared to matching external natural history control group
    - Proportion of eyes in which Baseline VA better than 1.0 logMAR was maintained at Month 12 compared to matching external natural history control group
    ? Proportion of eyes in patients treated with Raxone® >1 year after the onset of symptoms with CRR of VA from Baseline or in which Baseline VA better than 1.0 logMAR was maintained at Month 12 compared to external natural history control group, in all patients and classified by mutation
    ? Proportion of eyes and patients treated with Raxone® ?1 year after the onset of symptoms with CRR of VA from Baseline or in which Baseline visual acuity better than 1.0 logMAR was maintained following 6, 18 and 24 months of treatment with Raxone® compared to matching external natural history control group, in all patients and classified by mutation
    ? Proportion of eyes/patients treated with Raxone® ?1 year or >1 year after the onset of symptoms with ?Off-chart? VA at Baseline in whom VA improves to better than 1.60 logMAR by Month 6, 12, 18 and 24
    ? Proportion of eyes/patients treated with Raxone® ?1 year or >1 year after the onset of symptoms with VA in the categories of better than 1.0 logMAR, 1.0 to 1.68 logMAR and above 1.68 logMAR at each assessment time point up to Month 24
    ? Safety as assessed by AE count and laboratory analyses during the study
    ? Componentes del criterio de valoración principal:
    - Proporción de ojos con RCR de la AV respecto al valor inicial en el mes 12 en comparación con el grupo de control de evolución natural externo correspondiente.
    - Proporción de ojos en los que la AV inicial mejor de 1,0 logMAR se mantenía en el mes 12 en comparación con el grupo de control de evolución natural externo correspondiente.
    ? Proporción de ojos en pacientes tratados con Raxone® > 1 año después de la aparición de los síntomas con RCR de la AV respecto al valor inicial o en los que la AV inicial mejor de 1,0 logMAR se mantenía en el mes 12 en comparación con el grupo de control de evolución natural externo, en todos los pacientes y clasificados por mutación.
    ? Proporción de ojos y pacientes tratados con Raxone® ?1 año después de la aparición de los síntomas con RCR de la AV respecto al valor inicial o en los que la agudeza visual inicial mejor de 1,0 logMAR se mantenía después de 6, 18 y 24 meses de tratamiento con Raxone® en comparación con el grupo de control de evolución natural externo, en todos los pacientes y clasificados por mutación.
    ? Proporción de ojos/pacientes tratados con Raxone® ? 1 o > 1 año después de la aparición de los síntomas con AV ?sin optotipo? al inicio del estudio en los que la AV mejora hasta un valor mejor de 1,60 logMAR en los meses 6, 12, 18 y 24.
    ? Proporción de ojos/pacientes tratados con Raxone® ? 1 o > 1 año después de la aparición de los síntomas con AV en las categorías de mejor de 1,0 logMAR, de 1,0 a 1,68 logMAR y por encima de 1,68 logMAR en cada punto temporal de evaluación hasta el mes 24.
    ? Seguridad evaluada mediante el recuento de AA y pruebas analíticas durante el estudio.
    E.5.2.1Timepoint(s) of evaluation of this end point
    see E.5.2 text
    Ver el texto E.5.1
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) Yes
    E.8 Design of the trial
    E.8.1Controlled No
    E.8.1.1Randomised No
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned2
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA25
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA No
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    last visit of the last subject undergoing the trial
    ultima visita del último paciente en el estudio
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years2
    E.8.9.1In the Member State concerned months1
    E.8.9.1In the Member State concerned days
    E.8.9.2In all countries concerned by the trial years2
    E.8.9.2In all countries concerned by the trial months1
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 Yes
    F.1.1Number of subjects for this age range: 50
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) Yes
    F.1.1.6.1Number of subjects for this age range: 50
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 188
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 12
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally Yes
    F.3.3.6.1Details of subjects incapable of giving consent
    Paediatric population
    Población Pediatrica
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state4
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 250
    F.4.2.2In the whole clinical trial 250
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    At the end of the study, in countries where the drug will not be at that time available on the market, every effort will be made to assure continued access to Raxone® to the patients who derived and are still deriving a benefit from treatment administration. Where required and according to the local specific regulation, special access programmes (e.g. Named Patient Programs (NPP)) may be put in place.
    Al final del estudio, en países en los que el fármaco no estará disponible en el mercado en ese momento, se hará todo lo posible por garantizar el acceso continuado a Raxone® a los pacientes que hayan obtenido y sigan obteniendo un beneficio de la administración del tratamiento. Cuando sea necesario, y según la normativa local específica, se pueden poner en práctica programas de acceso especiales (p. ej., programas para pacientes concretos, [Named Patient Programs, NPP]).
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2016-05-30
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2016-06-29
    P. End of Trial
    P.End of Trial StatusOngoing
    For support, visit the EMA Service Desk , log in using your EMA account and open a ticket specifying "EU CTR" in your request.
    If you do not have an account, please visit the EMA Account management page page click on "Create an EMA account" and follow the instructions.
    The status of studies in GB is no longer updated from 1.1.2021
    For the UK, as from 1.1.2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2022 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    Legal notice
    EMA HMA